Profile data is unavailable for this security.
About the company
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
- Revenue in USD (TTM)3.08bn
- Net income in USD-986.58m
- Incorporated1995
- Employees6.90k
- LocationExact Sciences Corp5505 Endeavor LaneMADISON 53719United StatesUSA
- Phone+1 (608) 284-5700
- Fax+1 (608) 284-5701
- Websitehttps://www.exactsciences.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Madrigal Pharmaceuticals Inc | 740.64m | -289.13m | 10.55bn | 528.00 | -- | 16.86 | -- | 14.25 | -13.01 | -13.01 | 33.39 | 27.56 | 0.6082 | 0.9008 | 10.30 | 1,402,727.00 | -23.74 | -68.48 | -30.98 | -85.32 | 95.25 | -- | -39.04 | -876.55 | 3.26 | -- | 0.3519 | -- | -- | -- | -24.69 | -- | 106.52 | -- |
| Summit Therapeutics Inc | 0.00 | -921.62m | 11.14bn | 159.00 | -- | 57.93 | -- | -- | -1.24 | -1.24 | 0.00 | 0.2583 | 0.00 | -- | -- | 0.00 | -241.08 | -78.31 | -287.72 | -86.84 | -- | -- | -- | -31,307.77 | -- | -- | 0.00 | -- | -- | -- | 64.01 | -- | -16.43 | -- |
| Exelixis Inc | 2.32bn | 782.57m | 11.41bn | 1.08k | 15.78 | 5.33 | 14.05 | 4.92 | 2.78 | 2.78 | 8.23 | 8.23 | 0.8011 | 3.80 | 8.40 | 2,154,249.00 | 27.02 | 13.68 | 31.41 | 15.65 | 96.39 | 96.33 | 33.73 | 20.55 | 3.50 | -- | 0.00 | 0.00 | 6.98 | 18.63 | 50.13 | 47.58 | -22.60 | -- |
| Medpace Holdings Inc | 2.53bn | 451.12m | 12.15bn | 5.90k | 27.99 | 26.39 | 25.35 | 4.80 | 15.29 | 15.29 | 85.67 | 16.22 | 1.24 | -- | 7.24 | 428,853.20 | 22.13 | 18.52 | 55.42 | 37.53 | 30.06 | 29.60 | 17.83 | 17.15 | -- | -- | 0.00 | 0.00 | 19.97 | 22.27 | 11.57 | 25.50 | 0.0102 | -- |
| Ionis Pharmaceuticals Inc | 966.96m | -256.34m | 13.06bn | 1.07k | -- | 21.02 | -- | 13.50 | -1.71 | -1.71 | 5.87 | 3.84 | 0.3163 | 0.6054 | 45.47 | 904,542.60 | -8.39 | -11.71 | -10.45 | -13.72 | 98.78 | 98.42 | -26.51 | -44.15 | 2.78 | -- | 0.7414 | -- | -10.48 | -8.88 | -23.92 | -- | 7.94 | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -3.58m | 15.44bn | 12.00 | -- | 3,176.36 | -- | -- | -0.0073 | -0.0073 | 0.00 | 0.0098 | 0.00 | -- | -- | 0.00 | -50.50 | -53.93 | -53.75 | -65.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 16.68 | -- | 5.32 | -- |
| Revolution Medicines Inc | 0.00 | -960.98m | 18.62bn | 809.00 | -- | 11.44 | -- | -- | -5.18 | -5.18 | 0.00 | 8.42 | 0.00 | -- | -- | 0.00 | -47.87 | -28.38 | -52.53 | -30.68 | -- | -- | -- | -1,324.37 | -- | -- | 0.1384 | -- | -100.00 | -- | -37.52 | -- | 31.83 | -- |
| Exact Sciences Corp | 3.08bn | -986.58m | 19.70bn | 6.90k | -- | 7.82 | -- | 6.39 | -5.32 | -5.32 | 16.43 | 13.20 | 0.4873 | 6.67 | 10.80 | 446,671.40 | -15.60 | -11.29 | -17.40 | -12.38 | 67.37 | 71.21 | -32.01 | -30.90 | 2.44 | -- | 0.4833 | -- | 10.37 | 25.78 | -403.97 | -- | 0.9474 | -- |
| Iqvia Holdings Inc | 16.31bn | 1.36bn | 28.31bn | 91.00k | 21.25 | 4.35 | 11.40 | 1.74 | 7.86 | 7.86 | 93.98 | 38.34 | 0.5739 | -- | 4.94 | -- | 4.71 | 4.69 | 6.47 | 6.14 | 33.29 | 34.29 | 8.21 | 8.18 | -- | 3.36 | 0.7034 | -- | 5.87 | 7.50 | -0.9468 | 37.27 | -0.4257 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 15.98m | 8.37% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 14.33m | 7.51% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 7.28m | 3.81% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 5.19m | 2.72% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 4.18m | 2.19% |
| BlackRock Advisors LLCas of 31 Dec 2025 | 4.06m | 2.13% |
| Columbia Management Investment Advisers LLCas of 30 Sep 2025 | 3.76m | 1.97% |
| Citadel Advisors LLCas of 30 Sep 2025 | 3.76m | 1.97% |
| Norges Bank Investment Managementas of 31 Dec 2025 | 3.43m | 1.80% |
| Geode Capital Management LLCas of 31 Dec 2025 | 3.33m | 1.75% |
